Oruka Therapeutics, Inc. annual report, FY2019

Filing summary

Entity and period: The supplied filing is ARCA biopharma, Inc.’s Form 10-K for the fiscal year ended December 31, 2019, filed February 18, 2020. It is not an Oruka Therapeutics filing, and it reports annual results rather than standalone 2019 Q4 results.

Business context

ARCA was a clinical-stage biopharmaceutical company focused on genetically targeted cardiovascular therapies. Its lead candidate, Gencaro (bucindolol), was being developed for atrial fibrillation in heart-failure patients with a specific beta-1 receptor genotype. AB171 was an earlier-stage candidate for heart failure and peripheral arterial disease. ARCA had no approved products and reported no product revenue.

Financial performance and position

As a pre-revenue development company, operating margins are not meaningful. The company had no debt outstanding at December 31, 2019; current liabilities were $926,000. Financing activities provided $6.560 million in 2019, principally from common-stock sales, while the company also repaid $349,000 under a vendor financing arrangement.

Changes, outlook and key risks

• Net loss and operating cash use declined year over year, mainly because GENETIC-AF trial close-out and related costs incurred in 2018 did not recur. R&D expense fell by $2.406 million; G&A rose by $102,000.
• Year-end cash increased by $1.755 million, supported by equity financing. The company said cash, after potential cost reductions, was expected to fund operations only through the end of the third quarter of 2020. Management and the auditor cited substantial doubt about the company’s ability to continue as a going concern.
• ARCA planned to seek financing, a collaboration, or another strategic transaction to support operations and Gencaro development. Without funding or a transaction, it could delay or stop development or cease operations.
• Following a 2019 FDA Special Protocol Assessment, ARCA planned, subject to financing, to begin enrolling about 400 patients in the PRECISION-AF Phase 3 trial in Q4 2020, with topline results projected about two and a half years after enrollment began. The SPA did not guarantee approval.
• GENETIC-AF’s primary analysis showed a similar treatment benefit for Gencaro and TOPROL-XL in the overall trial population. ARCA highlighted favorable subgroup and post-hoc analyses, including a 46% reduction in the primary endpoint in its precision therapeutic phenotype cohort (p=0.011); these analyses require careful interpretation and confirmation.
• Management expected 2020 R&D expense to exceed 2019 if PRECISION-AF began; otherwise, it expected R&D expense to be roughly consistent with 2019. G&A was expected to remain broadly consistent.
• Other material risks include trial enrollment and efficacy uncertainty, regulatory and companion-diagnostic approvals, dependence on third parties, dilution from further equity financing, Nasdaq listing compliance, and commercialization and reimbursement challenges.

Important facts for investors to verify

• Confirm the issuer identity: this filing is for ARCA biopharma, Inc. (ticker ABIO), not Oruka Therapeutics.
• Review the audited financial statements and going-concern disclosure, including cash runway assumptions and the need for additional capital.
• Check subsequent filings for financing, strategic transactions, changes to the PRECISION-AF start date, and updates to cash and operating plans.
• Assess the full GENETIC-AF results and distinguish the overall trial findings from subgroup and post-hoc analyses.
• Review the FDA SPA terms and the separate regulatory path and availability requirements for the Gencaro genetic test.